169 related articles for article (PubMed ID: 25140833)
21. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
Kamijo H; Miyagaki T; Shishido-Takahashi N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
Blood; 2018 Nov; 132(18):1922-1935. PubMed ID: 30194255
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species- and iron-dependent cell death in cutaneous T-cell lymphoma.
Kiessling MK; Klemke CD; Kaminski MM; Galani IE; Krammer PH; Gülow K
Cancer Res; 2009 Mar; 69(6):2365-74. PubMed ID: 19258503
[TBL] [Abstract][Full Text] [Related]
23. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
[TBL] [Abstract][Full Text] [Related]
24. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
[TBL] [Abstract][Full Text] [Related]
25. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.
Zhang C; Li B; Gaikwad AS; Haridas V; Xu Z; Gutterman JU; Duvic M
J Invest Dermatol; 2008 Nov; 128(11):2728-2735. PubMed ID: 18496567
[TBL] [Abstract][Full Text] [Related]
26. Reversible resistance to apoptosis in cutaneous T cell lymphoma.
Meech SJ; Edelson R; Walsh P; Norris DA; Duke RC
Ann N Y Acad Sci; 2001 Sep; 941():46-58. PubMed ID: 11594582
[TBL] [Abstract][Full Text] [Related]
27. Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells.
Braun FK; Fecker LF; Schwarz C; Walden P; Assaf C; Dürkop H; Sterry W; Eberle J
J Invest Dermatol; 2007 Oct; 127(10):2425-37. PubMed ID: 17495957
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
29. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
[TBL] [Abstract][Full Text] [Related]
30. Decreased expression of Fas (APO-1/CD95) on peripheral blood CD4+ T lymphocytes in cutaneous T-cell lymphomas.
Dereure O; Portales P; Clot J; Guilhou JJ
Br J Dermatol; 2000 Dec; 143(6):1205-10. PubMed ID: 11122022
[TBL] [Abstract][Full Text] [Related]
31. Proteasome inhibitors block Ras/ERK signaling pathway resulting in the downregulation of Fas ligand expression during activation-induced cell death in T cells.
Tanimoto Y; Kizaki H
J Biochem; 2002 Mar; 131(3):319-26. PubMed ID: 11872160
[TBL] [Abstract][Full Text] [Related]
32. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Zhang C; Hazarika P; Ni X; Weidner DA; Duvic M
Clin Cancer Res; 2002 May; 8(5):1234-40. PubMed ID: 12006543
[TBL] [Abstract][Full Text] [Related]
33. Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP.
Sumarni U; Reidel U; Eberle J
Cells; 2021 Apr; 10(5):. PubMed ID: 33922439
[TBL] [Abstract][Full Text] [Related]
34. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
35. Epigenetically Enhanced Photodynamic Therapy (ePDT) is Superior to Conventional Photodynamic Therapy for Inducing Apoptosis in Cutaneous T-Cell Lymphoma.
Salva KA; Wood GS
Photochem Photobiol; 2015 Nov; 91(6):1444-51. PubMed ID: 26302991
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells.
Berger CL; Tigelaar R; Cohen J; Mariwalla K; Trinh J; Wang N; Edelson RL
Blood; 2005 Feb; 105(4):1640-7. PubMed ID: 15514008
[TBL] [Abstract][Full Text] [Related]
37. Localization of clonal T cells to the epidermis in cutaneous T-cell lymphoma.
Fivenson DP; Hanson CA; Nickoloff BJ
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):717-23. PubMed ID: 7929915
[TBL] [Abstract][Full Text] [Related]
38. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
[TBL] [Abstract][Full Text] [Related]
39. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior.
Vermeer MH; van Doorn R; Dukers D; Bekkenk MW; Meijer CJ; Willemze R
J Clin Oncol; 2001 Dec; 19(23):4322-9. PubMed ID: 11731515
[TBL] [Abstract][Full Text] [Related]
40. Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.
Yumeen S; Girardi M
Yale J Biol Med; 2020 Mar; 93(1):111-121. PubMed ID: 32226341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
